Fox Chase Cancer Center News

CHICAGO, IL (April 3, 2012) – The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia.

PHILADELPHIA (April 2, 2012) — Registered nurse Sue Coady is the first Fox Chae nurse to receive the DAISY Award for Extraordinary Nurses. The award celebrates the clinical skill and compassionate care given by nurses in all types of settings.

CHICAGO, IL (April 2, 2012) – Latest findings from Fox Chase Cancer Center reveal that targeting inflammatory pathways may lead to new therapies.

CHICAGO, IL (April 2, 2012) – Results could lead to personalized treatment strategies for patients with this type of cancer.

CHICAGO, IL (April 2, 2012) – Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease. 

CHICAGO, IL (April 1, 2012) —  New research from scientists at Fox Chase Cancer Center shows that a protein called survivin could be a useful tool in understanding pancreatic cancer—particularly for identifying which subsets of patients will most likely respond to treatment. The scientists found that patients who underwent different treatment regimens, following surgery, had different levels of survivin and experienced different lengths of disease-free survival.

CHICAGO, IL (April 1, 2012)—At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, however, the disease often becomes resistant to estrogen deprivation from the drugs—making treatment options more limited. New findings by researchers from Fox Chase Cancer Center identify a pair of proteins that could play a crucial role in restoring treatment sensitivity to these resistant cancerous cells—possibly leading to more treatment options in the future.

CHICAGO, IL (April 1, 2012)—Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments.